Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Vorinostat with Chemoradiation for Pancreatic Cancer
NCT02349867Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2015
- Primary completion
- May 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib and vorinostat in pancreatic adenocarcinoma (PDAC), sponsored by Virginia Commonwealth University. Primary endpoint: Recommended Phase 2 Dose and Schedule. Started Jan 2015; status: completed.
02
Drugs
sorafenibvorinostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02349867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349867.